Key terms

About EBS

Emergent BioSolutions Inc. engages in the development, manufacture, and commercialization of medical countermeasures. It offers products for civilian and military populations that address accidental, intentional, and naturally occurring public health threats. The firm's products include ACAM2000, BioThrax, Raxibacuma, Vaxchora, and VIGIV. Its business units include Vaccines and Anti-Infectives, Antibody Therapeutics, Devices, and Contract Development and Manufacturing. The company was founded by Fuad El-Hibri on September 5, 1998 and is headquartered in Gaithersburg, MD.

Sector
Industry
Employees
Founded
Website
Key stock statistics
1-day range
     
52-week range
     
Market cap
P/E ratio
Next earnings date
Dividend yield
Ex-dividend date
Dividend pay date

Key terms

Smart score

Latest EBS news

Mar 25 8:38am ET Emergent BioSolutions receives NAI status for Baltimore Bayview facility Mar 07 10:14am ET Emergent BioSolutions upgraded to Buy at Benchmark after ‘upbeat’ Q4 report Mar 07 10:11am ET Emergent BioSolutions upgraded to Buy from Hold at Benchmark Mar 06 5:07pm ET Emergent BioSolutions sees Q1 revenue $200M-$250M, consensus $185.4M Mar 06 5:06pm ET Emergent BioSolutions sees FY24 revenue $900M-$1.1B, consensus $1.18B Mar 06 5:04pm ET Emergent BioSolutions reports Q4 EPS (77c), consensus (19c) Mar 06 4:34pm ET Emergent BioSolutions Secures Flexible Credit Terms and Guarantor Mar 06 2:04pm ET Emergent BioSolutions options imply 36.4% move in share price post-earnings Mar 04 2:34pm ET Emergent BioSolutions options imply 25.1% move in share price post-earnings Feb 23 11:04am ET Biotech Alert: Searches spiking for these stocks today Feb 21 7:46am ET Emergent Biosolutions Welcomes Joseph Papa as New CEO Feb 21 7:15am ET Emergent BioSolutions appoints Papa as new president, CEO Jan 17 11:00am ET Emergent extending shelf-life of newly manufactured NARCAN, FDA says Jan 11 10:20am ET Analysts Offer Insights on Healthcare Companies: Sarepta Therapeutics (SRPT) and Emergent Biosolutions (EBS) Jan 11 8:03am ET Emergent BioSolutions awarded procurement contract valued up to $235.8M Jan 08 10:15pm ET Lightning Could Strike Twice for Biotech Penny Stock Chimerix (NASDAQ:CMRX)

No recent press releases are available for EBS

EBS Financials

1-year income & revenue

Key terms

EBS Forecasts

analyst rating

  • buy
  • hold
  • sell

We're sorry, but this
information is
temporarily unavailable.

1-year stock price forecast

EBS Competitors

$ Market cap P/E ratio $ Price 1d change 52-week range

Key terms